Chen Ying-Shou, Chen Chien-Liang, Wang Jyh-Seng
Division of Nephrology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Case Rep Oncol. 2009 Oct 2;2(3):172-176. doi: 10.1159/000241551.
We report a case of nephrotic syndrome and acute renal failure apparently induced by sunitinib. A 67-year-old man with a history of metastatic renal cell carcinoma presented with progressive kidney dysfunction with proteinuria, general edema, and body weight gain of 21 kg after undergoing 3 weeks of sunitinib therapy. The patient had taken no other over-the-counter medications, and all other possible causes of nephrotic syndrome were excluded. The Naranjo Adverse Drug Reaction Probability Scale score for this event was 6, indicating a high probability that the observed presentations were associated with use of the drug. However, despite the discontinuation of sunitinib, his condition deteriorated, and hemodialysis was initiated for respiratory distress. A renal biopsy was performed, which revealed ischemic acute tubular necrosis with minimal change nephropathy. In conclusion, nephrologists and oncologists should be aware that nephrotic syndrome with ischemic acute tubular necrosis is a possible adverse effect of sunitinib. For early diagnosis of this condition and to avoid renal damage, we recommend differential diagnosis of serum creatinine and proteinuria in patients undergoing sunitinib therapy.
我们报告了一例明显由舒尼替尼诱发的肾病综合征和急性肾衰竭病例。一名67岁有转移性肾细胞癌病史的男性,在接受3周舒尼替尼治疗后,出现进行性肾功能不全,伴有蛋白尿、全身水肿,体重增加21kg。该患者未服用其他非处方药物,且排除了肾病综合征的所有其他可能病因。此事件的纳伦霍药物不良反应概率量表评分为6分,表明观察到的症状很可能与药物使用有关。然而,尽管停用了舒尼替尼,他的病情仍恶化,因呼吸窘迫开始进行血液透析。进行了肾活检,结果显示为缺血性急性肾小管坏死伴微小病变肾病。总之,肾病科医生和肿瘤科医生应意识到,伴有缺血性急性肾小管坏死的肾病综合征是舒尼替尼可能的不良反应。为了早期诊断这种情况并避免肾脏损害,我们建议对接受舒尼替尼治疗的患者进行血清肌酐和蛋白尿的鉴别诊断。